News

Published on 28 Jun 2023 on Benzinga via Yahoo Finance

Viracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next...

Article preview image

Viracta Therapeutics Inc (NASDAQ: VIRX) announced that the relapsed or refractory EBV+ peripheral T-cell lymphoma (R/R EBV+ PTCL) cohort of their pivotal NAVAL-1 clinical trial met the pre-specified efficacy threshold for advancement to Stage 2 of the study.

Read the rest of the article
NASDAQ.VIRX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday -...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all ana...

Benzinga 27 Dec 2024
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.77% By...

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.77%

Investing.com 27 Dec 2024
US Stocks To Open Lower As Index Future Decline: Analysts Remain Upbeat About...

U.S. stock futures tumbled on Friday in premarket hours after a mixed Thursday. All four index fu...

Benzinga 27 Dec 2024
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure

Viracta Therapeutics ( (VIRX) ) just unveiled an update. Viracta Therapeutics has announced the...

TipRanks · via Yahoo Finance 27 Dec 2024
Castellum, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday...

Editor’s note: This story has been corrected to state that Castellum Inc — not Constellium SE — a...

Benzinga 27 Dec 2024
Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store...

Party City Holdco Inc., the one-stop-shop for all things celebration, is calling it a wrap. The c...

Benzinga 27 Dec 2024
Viracta Therapeutics Inc (VIRX) Reports Q3 2023 Financial Results Amid Clinical Advances

Viracta Therapeutics Inc (NASDAQ:VIRX) announced preliminary clinical data from the NAVAL-1 trial...

GuruFocus.com via Yahoo Finance 9 Nov 2023
WAVE Life Sciences Ltd. Sees a 23% Stock Price Surge Over the Past Three Months

WAVE Life Sciences Ltd. (NASDAQ:WVE), a preclinical biopharmaceutical company, has seen a signifi...

GuruFocus.com via Yahoo Finance 23 Aug 2023
Viracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next...

Viracta Therapeutics Inc (NASDAQ: VIRX) announced that the relapsed or refractory EBV+ peripheral...

Benzinga via Yahoo Finance 28 Jun 2023
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing compa...

Zacks via Yahoo Finance 28 Sep 2022

Copyright Statfolio @ 2025

Social Accounts